Charlie Harper
BSc, MSc, DPhil
Trial Data Scientist
Charlie is a data scientist working in the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU) at Oxford Population Health.
His work aims to develop new trial methods to streamline large-scale randomised trials that produce reliable answers, including the use of healthcare systems data to recruit and follow-up participants. He lectures on the University of Oxford's MSc in Clinical Trials and MSc in Global Health Science and Epidemiology.
Charlie completed his undergraduate degree in Economics at the University of East Anglia and MSc in Economics at Bristol University. He obtained his DPhil in Population Health from Oxford Population Health, where he showed that UK healthcare systems data can be used to reliably follow-up participants in large cardiovascular trials.
Recent publications
-
Clinical trial results in context: comparison of baseline characteristics and outcomes of 38,510 RECOVERY trial participants versus a reference population of 346,271 people hospitalised with COVID-19 in England.
Pessoa-Amorim G. et al, (2024), Trials, 25
-
Association of daily steps with incident non-alcoholic fatty liver disease: Evidence from the UK Biobank cohort
Fulda ES. et al, (2024)
-
Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis.
Cholesterol Treatment Trialists’ (CTT) Collaboration. Electronic address: ctt@ndph.ox.ac.uk None. and Cholesterol Treatment Trialists’ (CTT) Collaboration None., (2024), Lancet Diabetes Endocrinol, 12, 306 - 319
-
Getting our ducks in a row: The need for data utility comparisons of healthcare systems data for clinical trials.
Sydes MR. et al, (2024), Contemp Clin Trials
-
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2024), Lancet Child Adolesc Health, 8, 190 - 200